Collaborations

Home
Company Info
- Management Team
- Bor-Wen Wu, PhD MBA
- John Bomalaski, MD
- Archie Prestayko, PhD
- Amanda Johnston, PhD
- W. Jenny Kung, PhD
- Wei He, PhD
- Jim Thomson, PhD
- Steve Wu
- Advisory Board
- Lloyd J. Old, MD
- George Demetri, MD
- Robert C. Jackson, PhD
- Hsing-Jien Kung, MD PhD
- Jedd D. Wolchok, MD PhD
- Subsidiaries
- Polaris Pharmaceuticals
- TDW Pharmaceuticals
- DRX Pharmaceuticals
- DRX (Shanghai)
Pipeline
Collaborations
Literature
- Polaris & Collaborators
- ADI-PEG 20 (oncology)
- Uricase-PEG 20:
- TNF-PEG 20:
- CK2 inhibitor:
- ADI-PEG 20 (antiviral):
- Related Publications
- ADI general:
- ADI (oncology) renal cell carcinoma:
- ADI (oncology) combination therapy:
- TNF cancer treatment:
- CK2 inhibitor:
- Histidase cancer treatment:
Company News
Contact

Polaris has ongoing collaborations with many organizations.

Through these collaborations, Polaris is able to capitalize on cutting edge advancements taking place in both academia and clinical centers.

Polaris is working with these institutions to identify cancer types in addition to HCC and metastatic melanoma that may benefit from ADI-PEG 20 treatment, and also to identify other therapies to be used in combination with ADI-PEG 20.